Back

BSH 2022 - 62nd British Society for Haematology Annual Scientific Meeting

Apr 03 - Apr 05, 2022 | ManchesterUK

LARVOL is not affiliated with 62nd British Society for Haematology Annual Scientific Meeting and all trademarks, logos, and brand names are property of their respective owners

Showing 52 abstracts linked to Trials

Efficacy and Safety of Maribavir as a Rescue Treatment for Investigator Assigned Therapy in Transplant Recipients With Refractory or Resistant Cytomegalovirus Infections in the SOLSTICE Study: Phase 3 Trial Results

  • Oral

Efficacy and safety of avapritinib as first-line treatment of patients with advanced systemic mastocytosis: Results of EXPLORER and PATHFINDER clinical study

  • Oral

Long-term Survival Benefit of Eculizumab Treatment in Patients With Paroxysmal Nocturnal Haemoglobinuria: Data From the International PNH Registry

  • Oral

Analysis Of Anaemia Persistence And Related Adverse Events In Patients With Paroxysmal Nocturnal Haemoglobinuria Treated With Pegcetacoplan

  • Oral

Etavopivat, an investigational, once-daily, selective pyruvate kinase-R activator, improves sickle red blood cell health and survival in patients with sickle cell disease: an analysis of exploratory studies in a phase 1 trial

  • Oral

Pharmacokinetic/Pharmacodynamic Simulations Guide Selection of the Dose for Administration of Efgartigimod Subcutaneously in a Phase 3 Clinical Trial in Patients with Primary Immune Thrombocytopenia

  • Oral

Does Early Intervention in Myelofibrosis Impact Outcomes? A Pooled Analysis of the COMFORT I and II Studies

  • Poster

Real-World Outcome of Patients with Myelofibrosis Treated with Ruxolitinib in the West of Scotland: A Retrospective Multicentre Analysis

  • Poster

Pegylated Interferon is an effective and well-tolerated cytroreductive agent in patients with myeloproliferative neoplasms aged over 60 years

  • Poster

Real-World Experience of Rapid Obinutuzumab Administration: Time to Change Obinutuzumab Infusion Rates

  • Poster